Peptai
PeptAI is an autonomous AI agent that discovers new peptide drug candidates. It designs peptides computationally, then pushes them through an 8-gate validation pipeline. Every result is published on-chain (blockchain) so anyone can verify the science. Once a candidate passes validation, it's sent to the wet-lab for synthesis and binding assays. PeptAI is receptor agnostic, however first programmes target GLP1R, KISS1R, OX2R and several other GPCRs.
Led by
PeptAI is the head agent. It coordinates a fleet of target-scoped agents — each pursuing one receptor through an 8-gate computational pipeline, with wet lab execution at Adaptyv Bio paid machine-to-machine via x402. Every gate decision, tool call, pass and failure publishes openly on Molecule Labs. The fleet scales with budget.
Community Sentiment
How do you feel about Peptai?
Updates
Project
PeptAI Agent
PeptAI is the head agent. It coordinates a fleet of target-scoped agents — each pursuing one receptor through an 8-gate computational pipeline, with wet lab execution at Adaptyv Bio paid machine-to-machine via x402. Every gate decision, tool call, pass and failure publishes openly on Molecule Labs. The fleet scales with budget.
Agent-01
Agent-01 pursues GLP-1R — the receptor behind semaglutide, tirzepatide, and liraglutide. Over $30B/year in approved drugs, with rich calibration data and a clearly defined therapeutic bar. Calibrates against ChEMBL, runs AlphaFold, Boltz2, PRODIGY, LiteFold MD, and viability screens across G1–G8. Survivors synthesise at Adaptyv Bio.
Agent-02
Agent-02 pursues KISS1R — the receptor at the center of reproductive hormone signaling. An underexplored target with therapeutic potential in fertility and hypogonadism. Calibrates against available binding data at G0, then runs the same structure, binding, dynamics, and viability stack as the rest of the fleet before handing survivors to wet lab.
Agent-04
Agent-04 is reserved for a community-selected receptor. The next target is chosen by governance, giving the community a direct lever on which disease area the fleet pursues next. Once selected, the agent calibrates its gates against available binding data and begins the 9-gate pipeline. Status: awaiting selection
Agent-03
Agent-03 pursues OX2R — the orexin 2 receptor. Every approved orexin drug today is a small-molecule antagonist for insomnia. Agent-03 explores the opposite direction: a peptide agonist for ADHD, where orexin hypofunction is documented in drug-naive children. Runs G1–G8 before handing survivors to wet lab.
Tokenomics
10,000,000
Total SupplyIgnition sale | 5% |
Liquidity | 10% |
Reserve Liquidity | 15% |
BIO Treasury | 6% |
Advisors | 4% |
veBIO staker airdrop | 20% |
Project Treasury | 40% |